CCHF


You are invited to take part in a study to investigate a new vaccine for Crimean-Congo haemorrhagic fever virus. The study is being led by the Oxford Vaccine Group, which is part of the University of Oxford, and is taking place at the Centre for Clinical Vaccinology and Tropical Medicine at the Churchill Hospital.

If you are 18 to 55 years old, in good health and live in the Oxfordshire area, then you may be eligible to take part. We will provide reimbursement between £1,110 and £1,470, for your time, inconvenience and travel. The total study participation time is 12 months.

Background

Crimean-Congo haemorrhagic fever (CCHF) is caused by a virus which is spread by ticks.

These live on a wide variety of wild and domestic animals, including cattle, sheep and goats.

People usually acquire the infection after being bitten by a tick, but the disease can also be caught directly from infected animals or people.

The infection does not always cause illness; but, in some cases, it causes very serious disease, often with impaired blood clotting, which can lead to serious bleeding. Up to 40 percent of people admitted to hospital with the disease will die. There are no proven, specific treatments for the disease, and no approved vaccines.

Crimean-Congo haemorrhagic fever occurs over a very wide geographic area, including parts of Southern Europe, the Middle East, Africa and south-west Asia. The World Health Organisation estimates that about 3 billion people live in areas at risk of the disease. Ten to fifteen thousand people are infected by the virus each year, of whom about 500 die as a consequence.

Study Goals

The University of Oxford has developed a vaccine against Crimean-Congo haemorrhagic fever called “ChAdOx2 CCHF”. This study will be the first time this vaccine is given to humans.

We are aiming to confirm the vaccine’s safety and investigate the development of immunity following vaccination.

For further information, please contact us to request the Participant Information Sheet or to speak to one of the study team.

Study Details

If you are eligible and decide to take part, you will receive two doses of the study vaccine, given 12 weeks apart. After receiving each dose of vaccine, you will be required to complete an online diary for 28 days. You will have blood tests to assess your immune response to the vaccine.

The Oxford Vaccine Group are based at the Centre for Clinical Vaccinology and Tropical Medicine at the Churchill Hospital, where all study visits/appointments will take place.

Further Information

If you would like to find out more, please read the Participant Information Sheet PIS

In addition, if you would like any further information regarding the study please contact us on:

Email: info@ovg.ox.ac.uk   Tel: 01865 611400

Kind Regards,

The Oxford Vaccine Group

 

Thank you for your interest. Unfortunately, you are not eligible to join this study. Your data have not been stored. If you are interested in hearing more about other "Oxford Vaccine Group" studies, you can sign up to our newsletter here http://newsletter.ovg.ox.ac.uk/OVG/lists/?p=subscribe&id=1

Thank you, but unfortunately, you need to be within easy traveling distance of the study site(s).

Unfortunately, we can’t consider you for this study until you have read the participant information leaflet provided at: PIS Please read the leaflet and then resume this questionnaire if you are still interested in participating in the trial.

2 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.